乳腺癌患者T细胞亚群变化的定量检测及其临床意义

本实验用流式细胞计对26名乳腺癌患者及14名正常对照者外周血T细胞亚群进行了检测,结果表明;(1)全组乳腺癌CD_3~ 及CD_4~ 细胞显著低于正常对照组,腋淋巴结移转组又明显低于腋淋巴结无转移组.(2)CD_8~ 细胞随乳腺癌不同阶段呈特征性改变.(3)腋淋巴结转移组CD_4~ /CD_8~ 比值明显低于正常对照及腋淋巴结无转移组.(4)CD_(16)~ 细胞在正常对照及伴在不伴腋淋巴转移乳腺癌组之间无显著差异.上述结果提示:(1)机体对乳腺癌有相应的防御机能.(2)乳腺癌患者CD_(16)~ (LGL)细胞数与NK细胞活性无关且和正常对照组无异.(3)乳腺癌患者CD_3~ /CD_8~ 比值可辅助评估伴腋淋巴转移乳腺癌患者的预后.

Count of T Cell Subsets in Patients with Breast Cancer and Its Clinical Significance

T cell subsets in peripheral blood were determined in 26 patients with breast cancer and 14 blood donors using FCM. It was shown that : 1. Percentages of CD3 and CD4 cells in this series of breast cancer were significantly lower than those in normal controls. Percentages of CD3 and CD4 cells in patients with metastatic axillary lymph nodes were significantly lower than those without axillary involvement. 2. Percentage of CD8 cells characteristically changed with progress of breast cancer. 3. Value of CD4 /CD8 in patients with positive axilla was remarkably lower than those in normal controls and negative axilla patients. 4. There was no significant difference of CD16 cells count between the normal controls and breast cancer patient disregarding metastatic status.The results indicate that ' 1. Human body has innate defending ability against breast cancer. 2. The number of CD16 cells (LGL)in patients with breast cancer has no relation with the NK cells activity. NK cells activity of these patients bears no diversity with normal controls. 3. CD4 /CDS value in patients with breast cancer plays an auxiliary role in prognostic evaluation when combined with metastatic status of axillary lymph nodes.